The University of Eastern Finland has announced a continuation of the Master research agreement with Ferring Ventures SA, focusing on the field of cell therapy. This partnership aims to enhance the development and production of these innovative solutions, leveraging the extensive expertise and resources of both parties. Ferring Ventures SA entities globally, including the Kuopio-based Ferring Ventures Oy will be instrumental in this collaboration. This setup ensures that groundbreaking research can be quickly translated into practical applications through close business collaboration.
Building on a well-established relationship, the University of Eastern Finland and Ferring Ventures SA have previously achieved significant progress in cell and gene therapy. The collaboration between the University of Eastern Finland and Ferring Ventures is expected to have a profound impact on the field of cell therapy.
By combining the university's cutting-edge research capabilities with Ferring Ventures SA’s industry expertise, the partnership aims to accelerate the development of new precision medicine, specifically cell therapy treatments. These treatments have the potential to address a wide range of medical conditions, offering new hope to patients with unmet clinical needs. Additionally, the collaboration is anticipated to foster innovation, drive economic growth in the region, and enhance the global competitiveness of both organisations.
According to Jukka Mönkkönen, Rector of the University of Eastern Finland, innovative therapies such as cell therapy hold significant potential both medically and in terms of the economy, and they can be a major growth sector in Finland. “The collaboration between the University of Eastern Finland and Ferring SA is a concrete example of how world-class research can have a societal and economic impact.”
Ferring Ventures SA values the long-standing collaboration with the University of Eastern Finland. "We are excited to continue our work with the university to develop advanced cell therapy solutions for the benefit of patients in new projects in the coming years," stated Jean-Frédéric Paulsen, Executive Chairman of Ferring Pharmaceuticals SA and Ferring Ventures SA.
For further information, please contact:
Professor, Vice Dean Markus Forsberg, University of Eastern Finland, markus.forsberg@uef.fi
Scientific Director Tuija Kekarainen, Ferring Ventures Oy, tuija.kekarainen@kct.fi
Ferring Ventures S/A is an investment and development holding company supporting the research, development, manufacturing and commercialisation of ground-breaking innovative technologies in the fields of gene and cell therapies. Both FinVector Oy and Ferring Ventures Oy (formerly known as Kuopio Center of Gene and Cell Therapy) based in Kuopio, Finland are 100 % owned by Ferring Ventures SA.
Ferring Ventures Oy (previously KCT) was founded in 2017 with a mission to develop innovative cell therapy solutions for cancer patients. Based in Kuopio, Finland, Ferring Ventures Oy today focuses on advancing cutting-edge cell therapy research and development to improve patient outcomes through groundbreaking therapies for cancer.
